Literature DB >> 2906874

Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.

C Bartoloni1, P Dupont, H Feltkamp, C I Johnston, K Steinbach, H Zilcher, F Kaindl.   

Abstract

The antihypertensive effect of ketanserin 40 mg b.d. in combination with a beta-adrenergic blocking agent or a diuretic was assessed in an open study in 35 patients with essential hypertension, who had not responded to treatment with beta-blockers, diuretics or their combination. The ketanserin/beta-blocker combination decreased mean sitting systolic/diastolic blood pressure (SBP/DBP) from 169/107 mmHg to 156/91 mmHg at the end of the 12-week active treatment period. The decrease in systolic blood pressure was significant only at Week 8, while the decrease in diastolic blood pressure was highly significant at all times. A significant reduction in heart rate by 10 beats.min-1 was observed with the ketanserin + beta-blocker combination. The ketanserin/diuretic combination led to a significant reduction in mean SBP/DBP from 164/106 mmHg to 146/92 mmHg after 12 weeks, with no significant change in heart rate. Body weight slightly increased in both groups. There were significantly fewer adverse reactions with the ketanserin/diuretic combination than with the ketanserin/beta-blocker combination. The results indicate a potentially useful therapeutic role for ketanserin in combination with beta-blockers or diuretics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906874     DOI: 10.1007/BF00637591

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorothiazide combination administered once daily.

Authors:  W P Leary; A J Reyes; K van der Byl; B Maharaj
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Ketanserin--a new antihypertensive agent.

Authors:  A Breckenridge
Journal:  J Hypertens Suppl       Date:  1986-04

3.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

4.  The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.

Authors:  L M Wing; J P Chalmers; M J West; A J Bune; B Ayres; J R Graham
Journal:  Clin Exp Hypertens A       Date:  1984

5.  Ketanserin in essential hypertension: a double-blind, placebo-controlled study.

Authors:  H A Cameron; L E Ramsay
Journal:  Postgrad Med J       Date:  1985-07       Impact factor: 2.401

6.  Chronic effect of ketanserin in mild to moderate essential hypertension.

Authors:  A J Woittiez; G J Wenting; A H van den Meiracker; H J Ritsema van Eck; A J Man in't Veld; F A Zantvoort; M A Schalekamp
Journal:  Hypertension       Date:  1986-02       Impact factor: 10.190

7.  Ketanserin versus metoprolol in the treatment of essential hypertension.

Authors:  J Milei; J Lemus; E Bernardiner
Journal:  J Hypertens Suppl       Date:  1986-04

8.  Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.

Authors:  T Hedner; B Persson
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.

Authors:  J De Cree; J Leempoels; W De Cock; H Geukens; H Verhaegen
Journal:  Angiology       Date:  1981-02       Impact factor: 3.619

10.  Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.

Authors:  L Andrén; A Svensson; B Dahlöf; R Eggertsen; L Hansson
Journal:  Acta Med Scand       Date:  1983
View more
  1 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.